Selfie-taking tourists could be spreading Covid-19 to gorillas krdo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from krdo.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update
February 12, 2021 GMT
LYON, France (BUSINESS WIRE) Feb 12, 2021
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the twelve months ended December 31, 2020 and provided a corporate update.
ADVERTISEMENT
“Despite the challenges posed by the COVID-19 pandemic, Poxel ended 2020 on a strong note, having accomplished several important corporate and clinical milestones and positioning the Company for an exciting 2021. We continued working closely with our partner Sumitomo Dainippon Pharma to further advance the review of the Japanese New Drug Application for Imeglimin follo
Median overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumab DURHAM, NC / ACCESSWIRE /
Date Time
Elderly esophageal cancer patients often receive suboptimal therapy due to perceived risks
Older patients who do receive recommended multimodal therapy, including surgery, have outcomes comparable with those of younger patients
CHICAGO: Elderly patients (70 years and over) with locally advanced esophageal (E) and esophagogastric junction (EGJ) cancer (located in the stomach and esophagus) should be considered for optimal therapy that has the potential to cure. This therapy regimen includes initial chemoradiotherapy (NACR) and surgical resection, an operation that removes the cancerous part of the organ.
According to researchers, this recommended therapy is often not offered to elderly patients out of concern that they will not tolerate such an intensive treatment regimen. In a new study, they found that older patients who received the therapy had outcomes comparable with those of younger patients (under 70 years old). The single-institution study from the Ochsner Clinic
Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.